Quil-A® adjuvant

Saponin vaccine adjuvant

Quil‑A® adjuvant is a saponin adjuvant produced under GMP by Croda (as part of the acquired Brenntag Biosector), a leader in the global vaccine adjuvants market, and purified by them through a proprietary process that ensures consistency and immunostimulatory potential.

Quil-A® adjuvant is used in a wide variety of veterinary vaccines, as well as in immunological research into human and veterinary applications [1,2]. Quil-A® adjuvant contains the water-extractable fraction of saponins from the South-American tree, Quillaja saponaria Molina.
These saponins belong to the group of triterpenoid saponins, that have a common triterpenoid backbone structure.

Saponins induce a strong adjuvant response to T-dependent as well as T-independent antigens [3]. Saponins also induce strong cytotoxic CD8+ lymphocyte responses and potentiate the response to mucosal antigens [2,3]. When combined with cholesterol and phospholipids to form ISCOMs (immunostimulatory complexes), Quil-A® adjuvant can activate both the cell‑mediated and the antibody-mediated immune responses to a broad range of viral, bacterial, parasitic, and tumor antigens [4].

InvivoGen products are for research purposes only; they are not for use in humans.
Note: Quil-A® is a registered trademark that belongs to Croda and is registered in a large number of countries and regions worldwide.

References:

1. Reed S. et al., 2013. Key roles of adjuvants in modern vaccines. Nat Med. 19(12):1597-608.
2. Singh M. & O’Hagan D., 2003. Recent advances in veterinary vaccine adjuvants. Int J Parasitol. 33:469-78.
3. Petrovsky N. & Aguilar JC., 2004. Vaccine adjuvants: Current state and future trends. Immunol Cell Biol.82(5):488-96.
4. Sun HX. et al., 2009. ISCOMs and ISOMATRIXTM. Vaccine 27(33):4388-401.